Literature DB >> 15372250

PTPRC (CD45) C77G mutation does not contribute to multiple sclerosis susceptibility in Sardinian patients.

Eleonora Cocco1, Maria Rita Murru, Cristina Melis, Lucia Schirru, Elisabetta Solla, Marina Lai, Marcella Rolesu, Maria Giovanna Marrosu.   

Abstract

A linkage and association of the CD45 (protein-tyrosine phosphatase, receptor-type C) C77G polymorphism and multiple sclerosis (MS) has been found in some studies but not in others. We analysed the C77G polymorphism in MS patients from the genetically homogeneous population of Sardinia. Using the transmission disequilibrium test, the mutation has been sought in 241 patients and 217 healthy sibs (HS) from singleton MS families and it was found in 5 (2.07 %) affected and 3 (1.38%) HS from 7 heterozygous parents (1.45 %). Transmission of the G77 allele was 71.4 % (TDT = 1.3, P = 0.26) in patients and 50% (TDT = 0, P = 1) in HS. Stratifying families according to carriage of MS-predisposing (DR+) or not-predisposing (DR-) HLA-DR-DQ genotype in patients, percentage of G77 transmission to DR+ patients was 33 (TDT = 0.33, P = 0.56, Pc = 1.12), while it was 100 (TDT = 4, P = 0.045, Pc = 0.09) in the DR-patients. We concluded that, despite the presence of CD45 G77 polymorphism in a few patients who did not carry the HLADR- DQ MS-predisposing molecules, CD45 did not contribute to development of the disease in Sardinian MS.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15372250     DOI: 10.1007/s00415-004-0485-1

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  25 in total

1.  The distribution of HLA class II haplotypes reveals that the Sardinian population is genetically differentiated from the other Caucasian populations.

Authors:  R Lampis; L Morelli; S De Virgiliis; M Congia; F Cucca
Journal:  Tissue Antigens       Date:  2000-12

2.  Genetic factors and the founder effect explain familial MS in Sardinia.

Authors:  M G Marrosu; M Lai; E Cocco; V Loi; G Spinicci; M P Pischedda; S Massole; G Marrosu; P Contu
Journal:  Neurology       Date:  2002-01-22       Impact factor: 9.910

3.  A point mutation in PTPRC is associated with the development of multiple sclerosis.

Authors:  M Jacobsen; D Schweer; A Ziegler; R Gaber; S Schock; R Schwinzer; K Wonigeit; R B Lindert; O Kantarci; J Schaefer-Klein; H I Schipper; W H Oertel; F Heidenreich; B G Weinshenker; N Sommer; B Hemmer
Journal:  Nat Genet       Date:  2000-12       Impact factor: 38.330

4.  PTPRC (CD45) is not associated with the development of multiple sclerosis in U.S. patients.

Authors:  L F Barcellos; S Caillier; L Dragone; M Elder; E Vittinghoff; P Bucher; R R Lincoln; M Pericak-Vance; J L Haines; A Weiss; S L Hauser; J R Oksenberg
Journal:  Nat Genet       Date:  2001-09       Impact factor: 38.330

5.  Does 77C-->G in PTPRC modify autoimmune disorders linked to the major histocompatibility locus?

Authors:  I Vorechovsky; J Kralovicova; E Tchilian; T Masterman; Z Zhang; B Ferry; S Misbah; H Chapel; D Webster; D Hellgren; M Anvret; J Hillert; L Hammarstrom; P C Beverley
Journal:  Nat Genet       Date:  2001-09       Impact factor: 38.330

6.  Protein tyrosine phosphatase receptor-type C exon 4 gene mutation distribution in an Italian multiple sclerosis population.

Authors:  Clara Ballerini; Eleonora Rosati; Marco Salvetti; Giovanni Ristori; Stefania Cannoni; Tiziana Biagioli; Luca Massacesi; Sandro Sorbi; Marco Vergelli
Journal:  Neurosci Lett       Date:  2002-08-16       Impact factor: 3.046

7.  Transmission test for linkage disequilibrium: the insulin gene region and insulin-dependent diabetes mellitus (IDDM).

Authors:  R S Spielman; R E McGinnis; W J Ewens
Journal:  Am J Hum Genet       Date:  1993-03       Impact factor: 11.025

8.  DRB1-DQA1-DQB1 loci and multiple sclerosis predisposition in the Sardinian population.

Authors:  M G Marrosu; M R Murru; G Costa; R Murru; F Muntoni; F Cucca
Journal:  Hum Mol Genet       Date:  1998-08       Impact factor: 6.150

9.  Structural variants of human T200 glycoprotein (leukocyte-common antigen).

Authors:  S J Ralph; M L Thomas; C C Morton; I S Trowbridge
Journal:  EMBO J       Date:  1987-05       Impact factor: 11.598

10.  Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis.

Authors:  W I McDonald; A Compston; G Edan; D Goodkin; H P Hartung; F D Lublin; H F McFarland; D W Paty; C H Polman; S C Reingold; M Sandberg-Wollheim; W Sibley; A Thompson; S van den Noort; B Y Weinshenker; J S Wolinsky
Journal:  Ann Neurol       Date:  2001-07       Impact factor: 10.422

View more
  3 in total

1.  Unusual case presentations associated with the CD45 C77G polymorphism.

Authors:  E Z Tchilian; J Gil; M L Navarro; E Fernandez-Cruz; H Chapel; S Misbah; B Ferry; H Renz; R Schwinzer; P C L Beverley
Journal:  Clin Exp Immunol       Date:  2006-12       Impact factor: 4.330

Review 2.  Alternative splicing in multiple sclerosis and other autoimmune diseases.

Authors:  Irina Evsyukova; Jason A Somarelli; Simon G Gregory; Mariano A Garcia-Blanco
Journal:  RNA Biol       Date:  2010-07-01       Impact factor: 4.652

3.  The CD45 77C/G allele is not associated with myasthenia gravis - a reassessment of the potential role of CD45 in autoimmunity.

Authors:  Ryan Ramanujam; Ritva Pirskanen; Lennart Hammarström
Journal:  BMC Res Notes       Date:  2010-11-10
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.